We believe the findings of this study will unveil multi-targeted iPSC-NK cells as a platform for allogeneic adoptive transfer immunotherapies, and reveal targetable TIGIT-CD155 interactions as combination therapies, thus paving the way for meaningful clinical advancements in NK cell therapies for GBM. The gene discussed is PVR; the disease is glioblastoma.